Mavenclad

Mavenclad lowers relapse rates, helps RRMS patients reach NEDA-3

Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced patients’ relapse rates and the development of new lesions while keeping disability stable over two years, according to a real-world study in Kuwait. Among patients who completed the two courses…

Mavenclad found comparable to Gilenya in highly active MS

Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups ā€” but…

Early treatment with Mavenclad, antibodies eased highly active MS

Early treatment with Mavenclad (cladribine) or monoclonal antibodies is more likely to control symptoms in people with highly active multiple sclerosis (MS), a study in Argentina suggests. Highly active disease usually is considered when frequent relapses occur and there is an increasing burden of brain magnetic resonance imaging…

WHO asked to add 3 MS treatments to its list of ‘essential medicines’

Aiming to promote equitable accessĀ toĀ multiple sclerosis (MS) treatments worldwide, an international MS alliance is asking that threeĀ disease-modifying therapies (DMTs) be added to the World Health Organization’s (WHO) list of essential medicines. Inclusion on the WHO list is considered an important if “initial” step in assuring that helpful treatments…

At 64, I’m Surprised to Be Scrambling to Mount a Chariot

As usual, Iā€™ve gone for what I hope to be an intriguing headline, because youā€™ve got to grab a reader by any means necessary. If youā€™ve read this far, Iā€™m winning! This saga goes back well over a year, when my neurologist suggested I participate in a clinical trial for…

Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherixā€™sĀ RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds

Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among…

Trial Will Test Mavenclad for Advanced Progressive MS

After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study,Ā ChariotMS (NCT04695080), aims to…

Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds

Skin reactions are common amongĀ relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated inĀ a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…

Early Use of High-efficacy DMTs Favor Lesser Disability Over Time

Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…

Slipping Over the Event Horizon Into SPMS

Isn’t it just like me to start my column with a physics analogy that is already confusing? Please stick with me, as all will be revealed. My point is that if a black hole is big enough, you might slip through its event horizon without even noticing. There would…

#AANAM ā€“ Exploring Mavenclad’s Effects on Immune Cells

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā€“22. GoĀ hereĀ to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

#AANAM ā€“ Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā€“22. GoĀ hereĀ to read the latest stories from the conference. A majority of theĀ relapsing-remitting multiple sclerosis (RRMS) patients givenĀ Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…

Mavenclad Effectively Lowers Relapse Rates, Study Comparing DMTs Finds

MavencladĀ (cladribine) appears to be better at lowering relapse rates during the first two years of disease in relapsing-remitting multiple sclerosis (RRMS) patients than other MS therapies, including interferon, Copaxone (glatiramer acetate) and Tecfidera (dimethyl fumarate), a head-to-head observational study found. Mavenclad, however, was less effective at…